03.08.2012 • News

Lundbeck in Deal with Teva over Copycat Antidepressant

Danish pharmaceutical group Lundbeck has agreed a deal with Israel's Teva over a copycat version of the Danish company's antidepressant drug Cipralex, it said on Thursday.

While a court injunction against copying Cipralex still stands, the parties have agreed a deal which will put an end to further court action, a Lundbeck spokesman said, while declining to give further details.

"I can confirm that we have reached a settlement but it is not a money settlement," the spokesman said.

Ratiopharm, owned by Teva, had produced copies of Cipralex while the drug was still patent protected.

Last week, EU antitrust regulators charged nine drug companies including Germany's Merck and Lundbeck with blocking the entry of a cheaper generic medicine to market.

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.